Semaglutide in the treatment of type 2 diabetes mellitus：rapid health technology assessment
- VernacularTitle:司美格鲁肽治疗2型糖尿病的快速卫生技术评估
- Author:
Sihua WANG
1
;
Sheng WANG
1
;
Yan WANG
1
;
Jiajie LUAN
2
Author Information
1. Dept. of Pharmacy，Wannan Medical College，Anhui Wuhu 241002，China;Dept. of Pharmacy，Yijishan Hospital of Wannan Medical College，Anhui Wuhu 241001，China
2. Dept. of Pharmacy，Wannan Medical College，Anhui Wuhu 241002，China
- Publication Type:Journal Article
- Keywords:
semaglutide;
type 2 diabetes mellitus
- From:
China Pharmacy
2023;34(12):1503-1508
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy， safety and cost-effectiveness of semaglutide in the treatment of type 2 diabetes mellitus （T2DM）， and to provide reference for clinical drug use. METHODS Rapid health technology assessment was adopted. Retrieved from PubMed， Embase， Cochrane Library， Web of Science， CNKI， Wanfang database， CBM， domestic and foreign HTA official websites， HTA reports， systematic evaluation/meta-analysis and pharmacoeconomic studies about semaglutide in the treatment of T2DM were collected during the inception to May 1st， 2022. After data extraction and quality evaluation， descriptive analysis was performed on the results of included studies. RESULTS A total of 22 pieces of literature were included， involving 7 meta-analyses and 15 pharmacoeconomic studies. In terms of efficacy and safety， semaglutide showed significant advantages in controlling glycated hemoglobin （HbA1c）， fasting blood glucose， postprandial mean glucose， body mass index and achieving a target of glycosylated hemoglobin level ＜7%； also， there was no increased risk of hypoglycaemia or the incidence of serious adverse effects， but the risk of gastrointestinal adverse effects was significantly higher than other interventions. In terms of cost-effectiveness， results of foreign studies showed that semaglutide was more cost-effective， compared with other glucagon-like peptide-1 receptor agonists， sodium-glucose transporter protein 2 inhibitors， dipeptidyl peptidase-4 inhibitors. Research based on the perspective of China’s health system showed that semaglutide had a clear cost-effectiveness advantage over dulaglutide when using GDP per capita in 2020 （72477 yuan） as the payment threshold. CONCLUSIONS The semaglutide has excellent efficacy and good safety for the treatment of T2DM， with cost-effectiveness advantages over a number of drugs， but attention should be paid to the occurrence of gastrointestinal adverse effects.
